Bedaquiline and delamanid were recently approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Korea. A treatment duration of 24 weeks was established based on phase 2 clinical trial data, although the combined use of these two drugs is typically not recommended because it may exaggerate QT prolongation. Here, we present a case of prolonged treatment (48 weeks) with a combination of bedaquiline and delamanid for pulmonary MDR-TB. The patient had previously been diagnosed with extensively drug-resistant TB but had been left untreated for the past 9 years due to a shortage of effective drugs. A combination of bedaquiline and delamanid successfully treated MDR-TB, highlighting the potential efficacy of these drugs for patients with drug-resistant TB infections. (Korean J Med 2019;94:294-298) 
INTRODUCTION
The incidence of tuberculosis (TB) in South Korea has steadily decreased in recent years; however, the overall incidence of multidrug-resistant tuberculosis (MDR-TB) remains steady, with 700-900 new cases per year [1] . Bedaquiline (Bdq) and delamanid (Dlm) are new drugs that can be used to treat MDR-TB in cases where standard treatment regimens are ineffective. The approved treatment duration for Bdq and Dlm is limited to just 24 weeks based on phase 2 clinical trial data [2] . In addition, because of a major concern about QT prolongation, the combination of Bdq and Dlm is only recommended for extraordinary situations in which the benefits outweigh the risks [3] . The number of patients using this new drug combination for MDR-TB Figure 1 . Previous history of anti-tuberculosis treatment and the results of DSTs. DST, drug susceptibility test; H, isoniazid; R, rifampin; E, ethambutol; Z, pyrazinamide; S, streptomycin; Km, kanamycin; Am, amikacin; Cm, capreomycin; Ofx, ofloxacin; Lfx, levofloxacin; Mfx, moxifloxacin; Cs, cycloserine; Pto, prothionamide; PAS, p-aminosalicylic acid; Cfz, clofazimine; Lzd, linezolid; CLR, clarithromycin; Amx-Clv, amoxicillin/clavulanate; SAM, amoxicillin/sulbactam; R, resistance; S, susceptibility. is increasing [4] ; however, no cases have been reported in which both drugs have been used concurrently for more than 24 weeks in Korea. Here, we present the case of a patient with pulmonary MDR-TB who was successfully treated with a combination of Bdq and Dlm for 48 weeks.
CASE REPORT
A 45-year-old woman was admitted to an isolation room for treatment of pulmonary MDR-TB. The patient was first diagnosed with MDR-TB 20 years prior, having been unsuccessfully treated with several conventional drug regimens at another hospital. She was transferred to our hospital in February 2004, after which treatment was reinitiated using a multidrug regimen including linezolid (Lzd) (Fig. 1) . Sputum acid-fast bacilli (AFB) stain/culture showed negative conversion immediately af- A chest radiograph revealed multiple cavitary lesions with tiny nodules, which were particularly dominant in both upper lung zones (Fig. 2) . The QT duration in electrocardiograms corrected using Fridericia's formula (QTcF) was 404. (Fig. 3) . The dose for each drug was as follows: Dlm, 100 mg twice a day; Bdq, 400 mg once a day for 2 weeks followed On the 38th day after treatment initiation, she was discharged to her home, where she maintained the same regimen with the exception of Mpm and Clv. A nurse monitored the patient's condition once a week by telephone.
The patient was followed up monthly at an outpatient clinic.
Two drugs were discontinued: Cs due to hand tremors and Pto due to nausea. On the 41st week after treatment initiation, Cfz was stopped due to skin hyperpigmentation (cosmetic reasons).
Bdq, Dlm, and Km were continued until the 48th week. A full breakdown of the treatment regimen is shown in Figure 3 In Korea, the treatment of MDR-TB using two new drugs, Bdq and Dlm, was approved by the TB expert review committee of the KCDC [3] . Despite approval, the prolonged use of these drugs beyond 24 weeks is prohibited. The concurrent use of both new drugs is permitted only when effective treatment is impossible using conventional drugs or only one of the new drugs.
This case report represents the first incident in which a patient with pulmonary MDR-TB was treated concurrently with Bdq and Dlm beyond 24 weeks in Korea. These observations are consistent with recent studies conducted outside of Korea, including several reports describing patients treated with one or both drugs for more than 24 weeks, as necessary [6] [7] [8] . No serious adverse events were reported in these cases. In this study, prolonged and concurrent use of the two new drugs resulted in successful treatment. In addition, despite the safety concerns, clinically significant QT prolongation was not observed. We expect that the concurrent and prolonged use of Bdq and Dlm will be expanded to include a larger number of difficult-to-treat MDR-TB patients.
To prevent the development of resistance and to maximize the efficacy of the new drugs, it is recommended that treatment regimens include additional companion drugs. In our case, Cfz Clinical trials are currently being conducted with new regimens, including Bdq or Dlm, to treat MDR-TB for 6-9 months [9, 10] . However, the duration of conventional regimens that include the new drugs is generally 18-24 months [3] . In our case, the total treatment duration was 48 weeks for three reasons: sputum culture conversion was achieved early, after 1 month of treatment; few effective drugs remained after completing 48 weeks of treatment with the two new drugs; and the cost of the drugs was too expensive for the patient to pay herself (the expenses for the initial 24 weeks were supported by the government, but additional costs needed to be paid by the patient). The appropriateness of the treatment duration will be determined after long-term follow up to screen for TB recurrence. 중심 단어: 베다퀼린; 델라마니드; 결핵; 다제내성
